PDMR Acquisition of Shares

RNS Number : 7505S

Shield Therapeutics PLC

05 October 2017

 

Shield Therapeutics plc

("Shield" or the "Company")

PDMR Acquisition of Shares

London, UK, 5 October 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that Carl Sterritt, Chief Executive Officer of the Company, has on 4 October 2017 exercised a call option to acquire 8,814 Ordinary Shares in the Company from Irorph GmbH for consideration of £1 per Ordinary Share. Details of the call option are set out in the Company's Admission Document. Following the transaction, Mr Sterritt holds 10,075,261 shares, representing 8.67 % of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Carl Sterritt
2	Reason for the notification
a)	Position/status	CEO and Director of Shield Therapeutics plc
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Acquisition of Ordinary Shares in accordance with the terms of a call option.
c)	Price(s) and volume(s)	£1 per Ordinary Share Volumes: 8,814
d)	Aggregated information -Aggregated volume -Price	8,814 £8,814
e)	Date of the transaction	4 October 2017
f)	Place of the transaction	Outside a trading venue

- Ends -

For further information please contact:

Shield Therapeutics plc                                                                                                   [phone]

Carl Sterritt, Chief Executive Officer

Karl Keegan, Chief Financial Officer

Nominated Advisor and Joint Broker                                                                        [phone]

Liberum Capital Limited

Christopher Britton/Steve Pearce

Joint Broker                                                                                                                          [phone]

Peel Hunt LLP

James Steel/Dr Christopher Golden

Financial PR Advisor                                                                                                        [phone]

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal 

US Investor Relations

Lazar Partners                                                                                                                      [phone]

Fern Lazar/ David Carey

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's.  Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX.  For more information please visit www.shieldtherapeutics.com.

About Feraccru®

Feraccru is Shield's lead product and is a novel therapy for the treatment of IDA. Feraccru received marketing authorisation across Europe in February 2016 for the treatment of IDA in adult patients with IBD and is in the early stages of commercialisation in European markets.  The Group is currently completing a pivotal Phase 3 clinical trial of Feraccru in IDA patients with pre-dialysis CKD and expects to announce results of this study around the turn of the year.  A positive result is expected to facilitate the filing of an NDA for Feraccru in the US as well as significantly broader commercialisation in Europe and beyond.

 

END

 

 

DSHLZLLBDBFFFBL